SEATTLE — Researchers presented positive findings from early-stage clinical trials of two novel HIV inhibitors at CROI.
At a news conference, Jennifer E. Sager, PhD, a clinical pharmacologist at Gilead Sciences, presented results of a phase 1 study on the safety, tolerability and pharmacokinetics of GS-6207, a first-in-class HIV capsid inhibitor, for use as a long-acting antiretroviral agent.
In the ongoing randomized, blinded, placebo-controlled trial, 40 healthy volunteers were randomly assigned to receive placebo (n = 8) or a single shot of GS-6207 (n = 32) at 30 mg, 100 mg, 300 mg or

Source link